Compounds > ruboxistaurin
Page last updated: 2024-09-04

ruboxistaurin and abt 869

ruboxistaurin has been researched along with abt 869 in 4 studies

Compound Research Comparison

Studies
(ruboxistaurin)		Trials
(ruboxistaurin)		Recent Studies (post-2010)
(ruboxistaurin)		Studies
(abt 869)		Trials
(abt 869)		Recent Studies (post-2010) (abt 869)
2032956841559

Protein Interaction Comparison

ProteinTaxonomyruboxistaurin (IC50)abt 869 (IC50)
Aurora kinase AHomo sapiens (human)0.76
Cyclin-dependent kinase 1Homo sapiens (human)9.8
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0321
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.9
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0492
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0313
Fibroblast growth factor receptor 1Homo sapiens (human)5.479
AromataseHomo sapiens (human)0.0418
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.015
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0364
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.1309
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0312
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0126
Cyclin-dependent kinase 8Homo sapiens (human)2.158
Angiopoietin-1 receptorHomo sapiens (human)0.0601
Cyclin-dependent kinase 19Homo sapiens (human)0.024

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

4 other study(ies) available for ruboxistaurin and abt 869

ArticleYear
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017